• Policy
• KMPG ‘We ask for the prompt reimbursement of Xpovio’
• by Kim, Jung-Ju Apr 22, 2024 05:45am

• Policy
• Will the 37th new drug in Korea receive approval?
• by Lee, Hye-Kyung Apr 22, 2024 05:45am

• Policy
• Reimb expansions of Keytruda have failed the 4th CDRC
• by Lee, Tak-Sun Apr 19, 2024 06:24am

• Policy
• Impurity detected in single-agent entacapones
• by Kang, Shin-Kook Apr 19, 2024 06:24am

• Policy
• Four Otezla generics were authorized simultaneously in Korea
• by Lee, Hye-Kyung Apr 19, 2024 06:24am

• Policy
• PVA exemptions expanded to drugs below KRW 3 billion
• by Lee, Tak-Sun Apr 18, 2024 05:54am

• Policy
• KRW 10 Bil antiemetic drug Akynzeo seeks reimb for injection
• by Lee, Tak-Sun Apr 18, 2024 05:54am

• Policy
• Will Fasenra be applied RSA for reimbursement in KOR?
• by Lee, Tak-Sun Apr 18, 2024 05:54am

• Policy
• Keytruda’s reimb expansion under review by CDRC
• by Lee, Tak-Sun Apr 17, 2024 06:06am

• Policy
• A Korean 4th gen NSCLC drug starts clinical trial
• by Lee, Hye-Kyung Apr 16, 2024 05:47am